Last updated on February 2015

A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moder-to-severe atopic dermatitis


Brief description of study

A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moder-to-severe atopic dermatitis

Detailed Study Description

A 28 week study with possibly 21 visits with treatment of atopic dermatitits with dupilumab.

Clinical Study Identifier: TX140106

Contact Investigators or Research Sites near you

Start Over

Janice K. Orem, CMA

Dermatology Clinical Research Center of San Antonio
San Antonio, TX USA
  Connect »